Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02058277 · ClinicalTrials.gov registry record · Phase 1
A Drug Interaction Study Between Bosutinib And Aprepitant In Healthy Volunteers
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT02058277 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 20 participants.
The verdict
NCT02058277, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This is an open label, randomized, single dose, one cohort, two sequence, two period crossover study in healthy subjects. The primary objective of the study is to evaluate the effect of a single oral dose of aprepitant on the pharmacokinetic (PK) profile of a single oral dose of bosutinib in healthy subjects.
Interventions
- DRUG bosutinib or bosutinib + aprepitant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2014-05 |
| Est. Completion | 2014-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02058277
The ClinicalTrials.gov registry entry for NCT02058277 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which bosutinib or bosutinib + aprepitant is the first listed.
NCT02058277 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02058277 about?
NCT02058277 is a clinical study titled "A Drug Interaction Study Between Bosutinib And Aprepitant In Healthy Volunteers". This is an open label, randomized, single dose, one cohort, two sequence, two period crossover study in healthy subjects. The primary objective of the study is to evaluate the effect of a single oral dose of aprepitant on the pharmacokinetic (PK) profile of a single oral dose of bosutinib in healthy...
What is the current status of trial NCT02058277?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2014-05. Estimated completion is 2014-06.
What interventions are being tested in trial NCT02058277?
The interventions under investigation include: bosutinib or bosutinib + aprepitant (DRUG).
Who is sponsoring clinical trial NCT02058277?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.